Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Marts 2023

Genmab — Marts 2023

Planlagt Fastgjort Låst Flyttet Genmab
499 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • P Offline
    P Offline
    Pensionisten
    wrote on sidst redigeret af
    #475

    Gad vide, om afgørelsen på voldgiften er medtaget i forudsætningerne.? Nå men vi er jo alle, hver især herrer over, hvor mange aktier vi vil have i selskabet. Kunne være en overvejelse, at skifte lidt ud med Novo - Genmab fylder lidt voldsomt i min portefølje 🙂

    1 Reply Last reply
    0
    • R Offline
      R Offline
      Riis7
      wrote on sidst redigeret af
      #476

      Du skulle ha haft Novo og ikke Genmab de sidste 5 år;-) og Novo betaler os udbytte;-)

      1 Reply Last reply
      0
      • R Offline
        R Offline
        Riis7
        wrote on sidst redigeret af
        #477

        Link Preview Image
        Dansk topledelse får aktieenheder for 77 millioner

        favicon

        Euroinvestor (www.euroinvestor.dk)

        1 Reply Last reply
        0
        • P Offline
          P Offline
          Pensionisten
          wrote on sidst redigeret af
          #478

          @Riis7. Jeg har ikke plads til flere Novo i pensionsdepoterne. Og de har ligget der, stille og roligt, i mange år 😉

          1 Reply Last reply
          0
          • R Offline
            R Offline
            Riis7
            wrote on sidst redigeret af
            #479

            Sådan , nok mange dansker der har det problem:-)

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #480

              Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 https://www.biospace.com/article/releases/bolt-biotherapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-business-update/

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #481

                Collaborations with Genmab and Innovent developing next-generation Boltbody ISACs continue to progress. Both collaborations are exploring proprietary linker-payloads from the Boltbody ISAC platform, combining with Genmab’s proprietary bispecific
                antibodies

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #482

                  The collaboration with Genmab exploring Boltbody ISACs using Genmab’s proprietary bispecific antibodies accounted for $4.2 million in revenue for 2022

                  1 Reply Last reply
                  0
                  • L Offline
                    L Offline
                    lahn1
                    wrote on sidst redigeret af
                    #483

                    BOLT også ude med vag PR på deres HER2 ISAC https://investors.boltbio.com/news-releases/news-release-details/bolt-biotherapeutics-announces-positive-topline-data-bdc-1001

                    1 Reply Last reply
                    0
                    • S Offline
                      S Offline
                      Sukkeralf
                      wrote on sidst redigeret af
                      #484

                      Måske vag fordi de skal præsentere data senere?

                      1 Reply Last reply
                      0
                      • L Offline
                        L Offline
                        lahn1
                        wrote on sidst redigeret af
                        #485

                        Ja måske 🙂

                        1 Reply Last reply
                        0
                        • P Offline
                          P Offline
                          Pensionisten
                          wrote on sidst redigeret af
                          #486

                          Den optur, der startede 10. marts synes sat lidt på pause. Håber på lidt positivt nyt, der kan give fornyede kræfter.

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #487

                            interesting, a new Epcoritamab trial +Venetoclax by the Haemato Oncology Foundation in the Netherlands, with Nordic & German CLL Study Groups, don't see genmab or abbvie - Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL (AETHER) https://clinicaltrials.gov/ct2/show/NCT05791409

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #488

                              Amivantamab efficacy in pretreated NSCLC with EGFR Exon 20 insertion mutations persists long term https://dailyreporter.esmo.org/european-lung-cancer-congress-2023/elcc-2023/amivantamab-efficacy-in-pretreated-nsclc-with-egfr-exon-20-insertion-mutations-persists-long-term

                              1 Reply Last reply
                              0
                              • SolsenS Offline
                                SolsenS Offline
                                Solsen
                                wrote on sidst redigeret af
                                #489

                                Rigtig spændende med combi med venetoclax, som er et fantastisk stof. Det kan der komme noget stort ud af for Genmab/Abbvie og patienterne.

                                1 Reply Last reply
                                0
                                • StockBullS Offline
                                  StockBullS Offline
                                  StockBull
                                  wrote on sidst redigeret af
                                  #490

                                  Det er i vores mørkeste øjeblikke, at vi skal fokusere for at se lyset.

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #491

                                    Venetoclax is also from AbbVie if i am not mistaken...

                                    1 Reply Last reply
                                    0
                                    • SolsenS Offline
                                      SolsenS Offline
                                      Solsen
                                      wrote on sidst redigeret af
                                      #492

                                      Correct

                                      1 Reply Last reply
                                      0
                                      • S Offline
                                        S Offline
                                        Sukkeralf
                                        wrote on sidst redigeret af
                                        #493

                                        In partnership with Roche/Genentech though

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #494

                                          https://twitter.com/tnewsomdavis/status/1641480986746662913 "Very surprised that 1/3 of audience opted
                                          for 1L Amivantamab"

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper